Vandria

Vandria is among the most clinically advanced pure-play bets on mitophagy as a druggable aging pathway, and it has already crossed the threshold most longevity companies never reach: a first-in-human trial. Its lead candidate VNA-318 is an orally available, brain-penetrant small molecule that induces mitophagy — the selective clearance of damaged mitochondria — to restore cellular energy production and lower chronic inflammation, and the company advanced it into a Phase 1 dosing healthy subjects, with first-in-human data in Alzheimer's now reported. The mechanistic thesis is compelling and increasingly mainstream: mitochondrial dysfunction is a recognized hallmark of aging implicated across neurodegeneration, and VNA-318's described dual mode of action — immediate cognitive benefit paired with long-term disease modification — targets a spectrum of high-unmet-need CNS indications including mild cognitive impairment, Alzheimer's, Parkinson's, and major depressive disorder. Vandria's financing was strengthened by a second Series A closing that brought the round to roughly $30.7M (CHF 28.3M) with the addition of the Hevolution Foundation and Dolby Family Ventures — validating backers focused specifically on aging biology — funding the Phase 1 program and the planned efficacy-focused Phase 1b/2a studies. CEO Klaus Dugi brings senior pharma development experience, and a clinical-stage mitophagy inducer with a broad CNS opportunity gives Vandria genuine optionality that a single-indication bet would lack.